JSGE Clinical Practice Guidelines 2014: standards, methods, and process of developing the guidelines

Yoshida, Masahiro; Kinoshita, Yoshikazu; Watanabe, Mamoru; Sugano, Kentaro

doi:10.1007/s00535-014-1016-1

Cited by 35 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CQs mainly relate to treatment, with no CQs about diagnosis. The guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [1]. The quality of evidence was graded as A (high), B (moderate), C (low), and D (very low).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

et al. 2016

Self Cite

View full text Add to dashboard Cite

The Japanese Society of Gastroenterology (JSGE) revised the evidence-based clinical practice guidelines for peptic ulcer disease in 2014 and has created an English version. The revised guidelines consist of seven items: bleeding gastric and duodenal ulcers, Helicobacter pylori (H. pylori) eradication therapy, non-eradication therapy, drug-induced ulcer, non-H. pylori, non-nonsteroidal anti-inflammatory drug (NSAID) ulcer, surgical treatment, and conservative therapy for perforation and stenosis. Ninety clinical questions (CQs) were developed, and a literature search was performed for the CQs using the Medline, Cochrane, and Igaku Chuo Zasshi databases between 1983 and June 2012. The guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Therapy is initially provided for ulcer complications. Perforation or stenosis is treated with surgery or conservatively. Ulcer bleeding is first treated by endoscopic hemostasis. If it fails, surgery or interventional radiology is chosen. Second, medical therapy is provided. In cases of NSAID-related ulcers, use of NSAIDs is stopped, and anti-ulcer therapy is provided. If NSAID use must continue, the ulcer is treated with a proton pump inhibitor (PPI) or prostaglandin analog. In cases with no NSAID use, H. pylori-positive patients receive eradication and anti-ulcer therapy. If first-line eradication therapy fails, second-line therapy is given. In cases of non-H. pylori, non-NSAID ulcers or H. pyloripositive patients with no indication for eradication therapy, non-eradication therapy is provided. The first choice is PPI therapy, and the second choice is histamine 2-receptor antagonist therapy. After initial therapy, maintenance therapy is provided to prevent ulcer relapse.

show abstract

Section: Introductionmentioning

confidence: 99%

“…The quality of evidence was graded as A (high), B (moderate), C (low), and D (very low). The strength of a recommendation was indicated as either ''1'' (strong recommendation) or ''2'' (weak recommendation) [1]. Consensus was previously defined as 70 % or more votes in agreement.…”

Section: Introductionmentioning

confidence: 99%

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Guidelines Creation Committee determined the grades of recommendations and the levels of evidence after deliberation using the Delphi method. As mentioned in a previous publication [1], the Guidelines were created in accordance with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. This draft was evaluated and amended by the Evaluation Committee, which was then presented to members of the JSGE.…”

Section: Introductionmentioning

confidence: 99%

Evidence-based clinical practice guidelines for management of colorectal polyps

et al. 2015

Self Cite

View full text Add to dashboard Cite

Background Recently in Japan, the morbidity of colorectal polyp has been increasing. As a result, a large number of cases of colorectal polyps that are diagnosed and treated using colonoscopy has now increased, and clinical guidelines are needed for endoscopic management and surveillance after treatment. Methods Three committees [the professional committee for making clinical questions (CQs) and statements by Japanese specialists, the expert panelist committee for rating statements by the modified Delphi method, and the evaluating committee by moderators] were organized. Ten specialists for colorectal polyp management extracted the specific clinical statements from articles published between 1983 and September 2011 obtained from PubMed and a secondary database, and developed the CQs and statements. Basically, statements were made according to the GRADE system. The expert panel individually rated the clinical statements using a modified Delphi approach, in which a clinical statement receiving a median score greater than seven on a nine-point scale from the panel was regarded as valid. Results The professional committee created 91CQs and statements for the current concept and diagnosis/treatment of various colorectal polyps including epidemiology, screening, pathophysiology, definition and classification, diagnosis, treatment/management, practical treatment, complications and surveillance after treatment, and other colorectal lesions (submucosal tumors, nonneoplastic polyps, polyposis, hereditary tumors, ulcerative colitis-associated tumor/carcinoma). Conclusions After evaluation by the moderators, evidence-based clinical guidelines for management of colorectal polyps have been proposed for 2014.

show abstract

“…In the theme containing marked recent progress or change, each working committee member added manual searching to get the latest literature until August 2015. The guidelines were developed with use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system [1]. The quality of evidence was graded as A (high), B (moderate), C (low), or D (very low).…”

Section: Introductionmentioning

confidence: 99%

“…The quality of evidence was graded as A (high), B (moderate), C (low), or D (very low). The strength of a recommendation was indicated as either ''1'' (strong recommendation) or ''2'' (weak recommendation) [1]. Consensus was previously defined as 70 % or more votes in agreement.…”

Section: Introductionmentioning

confidence: 99%

Evidence-based clinical practice guidelines for liver cirrhosis 2015

et al. 2016

Self Cite

View full text Add to dashboard Cite

The Japanese Society of Gastroenterology revised the evidence-based clinical practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases for the period between 1983 and June 2012. Manual searching of the latest important literature was added until August 2015. The guidelines were developed with use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. This digest version in English introduces selected clinical questions and statements related to the management of liver cirrhosis and its complications. Branched-chain amino acids relieve hypoalbuminemia and hepatic encephalopathy and improve quality of life. Nucleoside analogues and peginterferon plus ribavirin combination therapy improve the prognosis of patients with hepatitis B virus related liver cirrhosis and hepatitis C related compensated liver cirrhosis, respectively, although the latter therapy may be replaced by direct-acting antivirals. For liver cirrhosis caused by primary biliary cirrhosis and active autoimmune hepatitis, urosodeoxycholic acid and steroid are recommended, respectively. The most adequate modalities for the management of variceal bleeding are the endoscopic injection sclerotherapy for esophageal varices and the balloon-occluded retrograde transvenous obliteration following endoscopic obturation with cyanoacrylate for gastric varices. Beta-blockers are useful for primary prophylaxis of esophageal variceal bleeding. The V 2 receptor antagonist tolvaptan is a useful add-on therapy in careful diuretic therapy for ascites. Albumin infusion is useful for the prevention of paracentesis-induced circulatory disturbance and renal failure. In addition to disaccharides, the nonabsorbable antibiotic rifaximin is useful for the management of encephalopathy. Anticoagulation therapy is proposed for patients with acute-onset or progressive portal vein thrombosis.

show abstract

JSGE Clinical Practice Guidelines 2014: standards, methods, and process of developing the guidelines

Cited by 35 publications

References 23 publications

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

Evidence-based clinical practice guidelines for peptic ulcer disease 2015

Evidence-based clinical practice guidelines for management of colorectal polyps

Evidence-based clinical practice guidelines for liver cirrhosis 2015

Contact Info

Product

Resources

About